Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

Clinical Infectious Diseases - Tập 66 Số 2 - Trang 163-171 - 2018
David van Duin1, Judith J. Lok2, Michelle Earley2, Eric Cober3, Sandra S. Richter4, Federico Pérez5,6, Robert A. Salata5, Robert C. Kalayjian7, Richard Watkins8,9, Yohei Doi10, Keith S. Kaye11, Vance G. Fowler12,13, David L. Paterson14, Robert A. Bonomo15,16,5,6, Scott Evans2
1Division of Infectious Diseases, University of North Carolina, Chapel Hill
2Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
3Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio
4Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio
5Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio
6Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio
7Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio
8Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, Ohio
9Division of Infectious Diseases, Cleveland Clinic Akron General, Ohio
10Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania
11Division of Infectious Diseases, University of Michigan, Ann Arbor
12Division of Infectious Diseases, Duke University, Durham, North Carolina
13Duke Clinical Research Institute, Duke University, Durham, North Carolina
14University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital Campus, Australia
15Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio
16Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio

Tóm tắt

Từ khóa


Tài liệu tham khảo

Munoz-Price, 2013, Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases, Lancet Infect Dis, 13, 785, 10.1016/S1473-3099(13)70190-7

Tumbarello, 2015, Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study, J Antimicrob Chemother, 70, 2133, 10.1093/jac/dkv086

Gomez-Simmonds, 2016, Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections, Antimicrob Agents Chemother, 60, 3601, 10.1128/AAC.03007-15

Falcone, 2016, Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae, Clin Microbiol Infect, 22, 444, 10.1016/j.cmi.2016.01.016

Hauck, 2016, Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections, Clin Microbiol Infect, 22, 513, 10.1016/j.cmi.2016.01.023

van Duin, 2013, Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes, Diagn Microbiol Infect Dis, 75, 115, 10.1016/j.diagmicrobio.2012.11.009

Yao, 2016, Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1, Lancet Infect Dis, 16, 288, 10.1016/S1473-3099(16)00057-8

Liu, 2016, Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study, Lancet Infect Dis, 16, 161, 10.1016/S1473-3099(15)00424-7

Rojas, 2017, Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality, Clin Infect Dis, 64, 711

van Duin, 2016, Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations, Clin Infect Dis, 63, 234, 10.1093/cid/ciw243

Wu, 2016, Ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia, Clin Infect Dis, 63, 1147, 10.1093/cid/ciw491

Shields, 2016, Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections, Clin Infect Dis, 63, 1615, 10.1093/cid/ciw636

Rubin, 2016, States worse than death among hospitalized patients with serious illnesses, JAMA Intern Med, 176, 1557, 10.1001/jamainternmed.2016.4362

van Duin, 2014, Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network, Antimicrob Agents Chemother, 58, 4035, 10.1128/AAC.02636-14

Messina, 2016, Hospital readmissions in patients with carbapenem-resistant Klebsiella pneumoniae, Infect Control Hosp Epidemiol, 10.1017/ice.2015.298

van Duin, 2014, Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance, Clin Microbiol Infect, 20, O1117, 10.1111/1469-0691.12714

Chow, 1999, Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary, Int J Antimicrob Agents, 11, 7, 10.1016/S0924-8579(98)00060-0

Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8

Clinical and Laboratory Standards Institute, 2014, Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement, CLSI

Lascols, 2011, Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009), J Antimicrob Chemother, 66, 1992, 10.1093/jac/dkr240

Viau, 2012, “Silent” dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio, Clin Infect Dis, 54, 1314, 10.1093/cid/cis036

Evans, 2015, Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR), Clin Infect Dis, 61, 800, 10.1093/cid/civ495

Robins, 2000, Marginal structural models and causal inference in epidemiology, Epidemiology, 11, 550, 10.1097/00001648-200009000-00011

Hernán, 2000, Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men, Epidemiology, 11, 561, 10.1097/00001648-200009000-00012

Evans, 2015, Comment: fundamentals and innovation in antibiotic trials, Stat Biopharm Res, 7, 331, 10.1080/19466315.2015.1094406

Evans, 2016, Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation, Stat Biopharm Res, 8, 386, 10.1080/19466315.2016.1207561

Gutiérrez-Gutiérrez, 2017, Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study, Lancet Infect Dis, 17, 726, 10.1016/S1473-3099(17)30228-1

Carmeli, 2016, Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study, Lancet Infect Dis, 16, 661, 10.1016/S1473-3099(16)30004-4

Evans, 2017, Methods and issues in studies of CRE, Virulence, 8, 453, 10.1080/21505594.2016.1213473

Thông tin
Thông tin xuất bản

Clinical Infectious Diseases

Tập 66 Số 2

163-171

Thông tin tác giả